Sotera Health downgraded to Underweight from Equal Weight at Barclays

Barclays analyst Luke Sergott downgraded Sotera Health to Underweight from Equal Weight with a price target of $6, down from $7. The analyst expects a possible negative verdict on the upcoming Fornek case to weigh on the shares. Sotera management is “stuck between a rock and a hard place,” with the current strategy of fighting each case individually and on a case-by-case basis when possible “requiring shareholders to have a longer time-horizon and stronger constitutions than we have,” Sergott tells investors in a research note. The analyst does not see the stock working “until signs of light appear at the end of the tunnel.”